UBS Tags Repligen (RGEN) as Bioprocessing Leader for 2026, Cites 20% Order Growth and Reshoring Tailwinds

Repligen Corporation (NASDAQ:RGEN) is one of the best mid-cap growth stocks to buy right now. On January 16, UBS raised the firm’s price target on Repligen to $200 from $190, while maintaining a Buy rating. The firm believes that Repligen is uniquely positioned to lead a sustained recovery in the bioprocessing sector, supported by its diversified growth drivers and the accelerating reshoring trend. With over 20% order growth and an expanding footprint in Edge manufacturing, the firm sees Repligen as a core ...